TABLE 3.
IBD Medications, Location, and Phenotype of Ulcerative Colitis and Crohn Disease in the Study Cohort
| Ulcerative Colitis | Crohn Disease | |||
|---|---|---|---|---|
|
| ||||
| Medications | Azathioprine | 1 (3.4) | Azathioprine | 6 (14) |
| Methotrexate | 1 (3.4) | Methotrexate | 3 (7) | |
| 6-Mercaptopurine | 3 (10.3) | 6-Mercaptopurine | 3 (7) | |
| Sulfasalazine | 5 (17.2) | Sulfasalazine | 11 (25.6) | |
| Infliximab | 1 (3.4) | Infliximab | 10 (23.3) | |
| Adalimumab | 0 (0) | Adalimumab | 4 (9.3) | |
| Ustekinumab | 0 (0) | Certolizumab | 2 (4.7) | |
| Vedolizumab | 1 (3.4) | Vedolizumab | 3 (7) | |
| Ustekinumab | 2 (4.7) | |||
| Location | Ulcerative proctitis | 3 (10.3) | Ileal | 9 (20.9) |
| Left-sided ulcerative colitis | 9 (31) | Colonic | 10 (23.3) | |
| Extensive | 17 (58.6) | Ileocolonic | 24 (55.8) | |
| Isolated upper disease | 0 (0) | |||
| Phenotype | — | Nonstricturing, nonpenetrating | 21 (48.8) | |
| Stricturing | 15 (34.9) | |||
| Penetrating | 10 (23.3) | |||
| Perianal disease | 7 (16.3) | |||
Values are presented as n (%).